Condition
PD-L1 Negative
Total Trials
4
Recruiting
2
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Recruiting2
Active Not Recruiting2
Clinical Trials (4)
Showing 4 of 4 trials
NCT04468061Phase 2Recruiting
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT05382299Phase 3Active Not Recruiting
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT06288360Phase 2Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT03546426Phase 1Active Not Recruiting
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Showing all 4 trials